Company: DHR
Filing Date: 2025-10-21
Form Type: 10-Q
Source: 0000313616-25-000182
Chunk: 154

Company: DANAHER CORP /DE/
Filing Date: 2025-10-21
Form: 10-Q
Item: Item 2
Chunk 154
---
 filtration consumables more than offset lower demand for protein research equipment in the life science research end-markets.  

Operating Profit Performance

Operating profit margins decreased 400 basis points during the three-month period ended September 26, 2025 as compared to the comparable period of 2024.

Third quarter 2025 vs. third quarter 2024 operating profit margin comparisons were unfavorably impacted by:

•Third quarter 2025 impairment charge related to technology and other intangible assets - 475 basis points

Third quarter 2025 vs. third quarter 2024 operating profit margin comparisons were favorably impacted by:

•Higher third quarter 2025 core sales and the impact of product mix, net of the impact of changes in leverage from the Company’s operations and administrative cost structure and the impact of currency exchange rates - 75 basis points

31

Operating profit margins increased 110 basis points during the nine-month period ended September 26, 2025 as compared to the comparable period of 2024.

Year-to-date 2025 vs. year-to-date 2024 operating profit margin comparisons were favorably impacted by:

•Higher 2025 core sales and the impact of product mix, net of the impact of currency exchange rates - 300 basis points

Year-to-date 2025 vs. year-to-date 2024 operating profit margin comparisons were unfavorably impacted by:

•First nine months of 2025 impairment charges related to technology, other intangible assets and a facility - 190 basis points

Amortization of intangible assets as a percentage of sales decreased during both the three and nine-month periods ended September 26, 2025 as compared to the comparable periods of 2024, primarily as a result of the increase in sales.

LIFE SCIENCES

The Life Sciences segment offers a broad range of instruments, consumables, services and software that are primarily used by customers to study the basic building blocks of life, including DNA and RNA, nucleic acid, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies, and test and manufacture new drugs, vaccines and gene editing technologies.  Additionally, the segment provides products and consumables used to filter and remove contaminants from a variety of liquids and gases in many end-market applications.

As discussed in Note 8 to the accompanying Consolidated Condensed Financial Statements, during the third quarter of 2025, the Company reorganized and integrated certain businesses within its Life Sciences segment to better serve the Company’s customers in new